Tillbaka till Pressmeddelanden

Annexin receives Innovation Award at an international conference

STOCKHOLM December 14, 2022

Annexin Pharmaceuticals AB (Publ) ("Annexin" or "the Company") announces today that the Company was awarded the Innovation Award at the Ophthalmology Innovation Summit (OIS) in San Diego for its ongoing development of ANXV for retinal vein occlusion (RVO).

Dr. Anna Frostegård, Chief Scientific and Medical Officer, presented the RVO program and accepted the award. The jury selecting the award winners comprised investors and analysts with competence in the ophthalmological field (OIS Newsletter).

OIS, which was held in San Diego, USA, December 2-3, 2022, is a recognized forum for the most important new product ideas for treatment of diseases of the eye. Investors, analysts, and companies, some with products in the market and other more innovative, smaller companies, attended the congress. About 40 pre-selected companies were invited to present (OIS Presenting Companies)

“This award confirms the great potential and value of our project. Naturally, the international visibility provides a boost in view of partnering discussions and the future financing of the company,” says Anders Haegerstrand, CEO.


About Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals AB is a clinical stage biotechnology company world-leading in the Annexin A5 field for the treatment of various vascular diseases. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for short term treatment of patients with injuries and inflammation of the blood vessels. The company has an extensive patent portfolio for the treatment of diseases that occur due to the damage and inflammation of the blood vessels. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of ANXV.

The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company's Certified Adviser.



For further information, please contact:
Anders Haegerstrand, CEO, tel +4670 – 575 50 37

The information was submitted for publication at 09.00 on December 14, 2022.



Annexin Pharmaceuticals AB | Kammakargatan 48 | SE-111 60 Stockholm |
info@annexinpharma.com| annexinpharma.com